Cognition Therapeutics schedules FDA Type C meeting on Phase 3 endpoint for zervimesine in DLB psychosis

Bitget2026/09/29 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cognition Therapeutics will meet the FDA Division of Neurology on Oct. 20, 2026 in a Type C meeting.
Talks will focus on endpoint analytics and statistics for a planned Phase 3 trial of zervimesine in dementia with Lewy bodies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290730PRIMZONEFULLFEED9835344) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cognition Therapeutics schedules FDA Type C meeting on Phase 3 endpoint for zervimesine in DLB psychosis

You may also like

Crypto prices